🍪 CompoundTalk uses cookies to improve your experience, analyze traffic, and personalize content. By continuing to use this site, you agree to our Cookie Policy.
Evidence-based GLP-1 & peptide discussion since 2023
ForumsRetatrutide & Triple AgonistsGCG receptor signaling deep dive — anyone have experience?

GCG receptor signaling deep dive — anyone have experience?

zoe_NC Sun, Jan 4, 2026 at 9:44 AM 24 replies 1,337 viewsPage 1 of 5
zoe_NC
Member
278
1,234
Nov 2024
Charlotte, NC
Jan 4, 2026 at 9:44 AM#1

Putting this up for argument rather than for agreement. I have read it twice and I am still not certain what it supports.

The pharmacokinetics explain nearly every practical question asked here. Albumin binding above 99% slows clearance enough to make weekly dosing possible; a terminal half-life near a week means four to five weeks to steady state and therefore a four-week titration interval; subcutaneous bioavailability around 89% means injection site barely matters. Those three facts answer most timing questions before they are asked.

Where I think it is weakest: the completion rate deserves as much attention as the headline, because a large effect among those who finished is a different claim from a large effect among those enrolled.

The question I want answered is which effects tachyphylax and which persist, because the answer explains why tolerability improves while the appetite effect keeps working. I have searched first, so if this is covered somewhere point me at it and I will read it.

Note on sourcing:
Figures above are from the primary publication rather than the press summary. If a number here disagrees with one you have, post yours and we will work out which of us is reading a secondary source.
13 8Dr.BariatricHTX, LindaRN_retired, tommy_boulder and 10 others
Reply Quote Save Share Report
Dr.AddMedPHL
Senior Member
1,234
6,234
Mar 2024
Philadelphia, PA
Jan 4, 2026 at 10:45 AM#2
zoe_NC said:
The pharmacokinetics explain nearly every practical question asked here.

Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest trajectory ever seen for an anti-obesity agent[1].

Amylin receptor agonism enhances satiety signaling through the area postrema and reduces glucagon secretion. Combined with GLP-1R agonism, this dual mechanism may produce even greater efficacy than current agents.

Early-stage data — interpret with caution. But the trajectory is extraordinary.

References:
[1] Novo Nordisk investor presentation, September 2023.
Last edited: Jan 4, 2026 at 12:45 PM
12 7sarah_nash92, FitDadDave, RunnerRach and 9 others
Reply Quote Save Share Report
Dr.BariatricHTX
Senior Member
1,456
7,234
Feb 2024
Houston, TX
Jan 4, 2026 at 11:46 AM#3
zoe_NC said:
The pharmacokinetics explain nearly every practical question asked here.

This is where I part company with the consensus forming above. The mechanism is more central than most summaries suggest. Receptor agonism in the arcuate nucleus activates POMC neurons and inhibits AgRP/NPY signalling, and the downstream MC4R pathway is the same one disrupted in monogenic obesity — convergent genetic evidence that the target is the right one. Peripherally there is glucose-dependent insulin secretion, glucagon suppression and delayed gastric emptying, but the gastric component largely adapts over months while the central effect persists, which is why the durable effect is appetite rather than fullness.

11 6Dr.EM_Chicago, pete_RVA, CarlaRPh_TPA and 8 others
Reply Quote Save Share Report

Janoshik Analytical — Independent Testing

Trusted third-party HPLC & mass spectrometry analysis. Verify peptide purity with the lab the community relies on. Independent. Accurate. Transparent.

Verify Your Peptides

GL Biochem (Shanghai) Ltd. — Direct Manufacturer

Est. 1998. The synthesis house behind the vials you send for testing. ISO 9001 and cGMP certified, 1,500+ staff, batch-specific COA with every order.

Browse GL Biochem
Dr.EndoEP
Member
267
1,234
Oct 2024
El Paso, TX
Jan 4, 2026 at 12:47 PM#4
Dr.BariatricHTX said:
The mechanism is more central than most summaries suggest.

PK/PD modeling for the pharmacology: understanding the pharmacokinetics helps optimize dosing. Semaglutide:

  • Tmax: 24-72 hours post-injection
  • T½: ~168 hours (7 days) — enables weekly dosing
  • Steady state: reached at 4-5 weeks
  • Bioavailability (SubQ): ~89%
  • Volume of distribution: ~12.5L (primarily plasma)

The albumin binding (>99%) is the key pharmacological innovation — creating a sustained-release effect from a single injection. Previous GLP-1 agonists (exenatide) required BID dosing due to rapid clearance.

10 5Dr.BariatricHTX, LindaRN_retired, tommy_boulder and 7 others
Reply Quote Save Share Report
denise_HTX
Member
145
678
Jan 2025
Houston, TX
Jan 4, 2026 at 6:35 PM#5
Dr.AddMedPHL said:
Amycretin (AMY/GLP-1 dual agonist) emerging data relevant to the pharmacology: Phase 1 showed -13.1% body weight at only 12 weeks, the fastest…

Can confirm. Same sequence, different timescale. The detail I would add is minor and it is already implied above.

9 4TirzTom, TrialTracker_MD, JennaRN and 6 others
Reply Quote Save Share Report
1235

Similar Threads

TRIUMPH-3 topline results — 24.2% body weight loss at 48 weeks10 replies
Retatrutide mechanism: GLP-1/GIP/glucagon triple agonism explained5 replies
Retatrutide Phase 2 dose-response analysis — optimal dose range10 replies
Glucagon receptor agonism and hepatic lipid oxidation — MASH implications13 replies
Retatrutide vs tirzepatide — dual vs triple agonist comparison22 replies
ForumsNewTrendingMembersAccount

Log In

Forgot password?
No account? Register